Rearrangements of TCF3 (E2A) occur in o5% of childhood B-cell precursor acute lymphoblastic leukemia (BCP-ALL) cases.
Igm and the surrogate light chain together constitute the pre-B-cell receptor (pre-BCR). 5 Activation of this pre-BCR triggers the clonal expansion of pre-B cells in the bone marrow, after which these cells further maturate by initiating the rearrangement of the light chain locus genes IGK and IGL. 6 The transcription factor TCF3 is essential in the differentiation process of common lymphoid progenitors into B-lineage cells and is a key regulator of further B-cell development. TCF3-deficient cells are impaired in rearranging both the immunoglobulin heavy and light chain genes, and wild-type TCF3 regulates the expression of genes important in B-cell differentiation such as EBF1 and PAX5. 7, 8 These findings imply that TCF3-rearranged cases might be affected in pre-BCR-mediated signaling, which in turn could point to new therapeutic targets for this subtype of BCP-ALL. To address this hypothesis, we investigated components of the pre-BCR pathway in leukemic cells obtained from newly diagnosed children with TCF3-rearranged BCP-ALL and non-TCF3-rearranged BCP-ALL.
In a representative childhood BCP-ALL cohort, 11/13 (84.6%) of TCF3-rearranged cases were positive for CyIgm compared with 68/ 325 (20.9%) of non-TCF3-rearranged cases (Po0.001; Figure 1a) , thereby confirming previous studies. 3, 4 We used a previously validated PCR heteroduplex analysis 9 of V(D)J rearrangement patterns of the IGH, IGK and IGL genes to determine a difference in the heavy and light chain rearrangement patterns of TCF3 and non-TCF3-rearranged cases. Four stages at which the rearrangement had been arrested were defined: samples with only rearrangements of IGH (IGH), samples with V k -J k rearrangements but no IGK-Kde or V l -J l rearrangements IGK), samples with IGK-Kde and no V l -J l rearrangements IGK-Kde), and samples with V l -J l rearrangements (IGL). Strikingly, the immunoglobulin rearrangement pattern of TCF3-rearranged cases was arrested at the IGH stage in 86.4% (19/22) (Figure 1b ). These data demonstrate that the majority of TCF3-rearranged BCP-ALL cases express the immunoglobulin heavy chain without further initiating the rearrangement and expression of the light chain needed to mature further and form a functional B-cell receptor. This suggests a divergent role for the pre-BCR and its downstream signaling in TCF3-rearranged BCP-ALL.
Next, we analyzed the expression levels of several key components of the pre-BCR signaling complex: ZAP70, SYK, LYN, SLP65 (BLNK), BTK, PLCg2, PI3K-p110d, and IRF4 by reverse phase protein arrays 10 of leukemic cell lysates (containing 490% leukemic blasts) obtained from 19 TCF3-rearranged and 113 non-TCF3 BCP-ALL pediatric patients. As visualized in Figure 1c , most of these proteins were expressed significantly more in TCF3-rearranged compared with non-TCF3-rearranged BCP-ALL: ZAP70 1.3-fold (Po0.001), SLP65 3.4-fold (P ¼ 0.002), BTK 1.5-fold (Po0.001), PI3K-p110d 1.2-fold (P ¼ 0.02) and IRF4 5.2-fold (Po0.001). In addition, the expression of the TCF3-target gene EBF1 was 2.7-fold increased in TCF3-rearranged BCP-ALL cases (Po0.001; Figure 1c ).
The activity of this divergent pre-BCR pathway was evaluated by responsiveness to the BTK inhibitor Ibrutinib (PCI-32765, Selleckchem, Houston, TX, USA). Ibrutinib was demonstrated to be of clinical benefit to patients suffering from chronic lymphoblastic leukemia, 11, 12 B-cell non-Hodgkin lymphomas 11 and multiple myeloma. 13 We tested in primary BCP-ALL samples and leukemic cell lines in a 72-h in vitro drug cytotoxicity assay using methyl-thiazol-tetrazolium conversion as read-out. 14 In correspondence with preclinical studies showing effective antileukemic effect of Ibrutinib in primary chronic lymphoblastic leukemia cells, 15 a concentration range between 0 and 50 mM Ibrutinib was used. In our study the growth and viability of the TCF3-rearanged cell line MHH-CALL3 decreased upon exposure to increasing concentrations of Ibrutinib (Figure 2a ), resulting in a growth inhibitory concentration (GI50) of 43.5 mM. In contrast, no GI50 value was reached for non-TCF3-rearranged cell lines (Nalm6 and MHH-CALL4) nor the TCF3-rearranged cell line 697 (Figure 2a ). This latter cell line is known for its lack of functional BTK, 16, 17 suggesting relative specificity of Ibrutinib for BTK-mediated pre-BCR signaling in BCP-ALL. In correspondence, the level of phosphorylated ERK1/2, which is an important downstream effector of BTK contributing to cell survival, decreased upon a 4-h exposure to Ibrutinib in the TCF3-rearranged MHH-CALL3 but not in both non-TCF3-rearranged cell lines Nalm6 and MHH-CALL4 (as shown on western blot, Figure 2c ). Figure 2b shows the differential cytotoxic effect of Ibrutinib in primary patients' leukemic cells of six TCF3-rearranged and six non-TCF3-rearranged BCP-ALL patients (490% leukemic blasts) taken at the initial diagnosis (measured by methyl-thiazol-tetrazolium assay). All TCF3-rearranged samples expressed CyIgm in contrast to 50% (3/6) non-TCF3 samples, which represented two hyperdiploid (450 chromosomes), two ETV6-RUNX1-translocated, one BCR-ABL1-like and one BCR-ABL1-positive case. Ibrutinib significantly reduced the cell viability of all TCF3-rearranged cases at each inhibitor concentration compared with non-TCF3-rearranged cases (Po0.001). As leukemic cells of patients do not proliferate in ex vivo culture conditions, the concentration of Ibrutinib, which is Letter to the Editor lethal to 50% (LC50) of the primary leukemic cells, was calculated. The median LC50 value was 16.7 mM for TCF3-rearranged cases, whereas virtually no cell death was induced up to 50.0 mM of Ibrutinib in leukemic samples of non-TCF3-rearranged patients (Po0.001; Figure 2b ). Strikingly, in our study the leukemic cell samples of patients were more sensitive to cell death induced by Ibrutinib than the growth inhibitory concentration needed for cell lines. This suggests that TCF3-rearranged patients' leukemic cells have an activated pre-BCR signaling pathway. The observed LC50 values for TCF3-rearranged cells are comparable to previously reported drug cytotoxicity data in primary chronic lymphoblastic leukemia cells. 15 In addition, Ibrutinib was shown to impair the migration and adhesion of mature B cells to mesenchymal stromal cells at sub-micromolar levels. 18, 19 Taken together, these studies suggest that Ibrutinib is highly effective to target leukemic cells by interfering with (pre)BCR-driven survival/proliferation signaling and with migration/adhesion pathways.
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Remarkably, we observed that TCF3-rearranged BCP-ALL cases intrinsically express higher protein levels of pre-BCR pathway including IRF4 (Figure 1c) . In normal B-cell development, IRF4 triggers the rearrangement of the immunoglobulin light chain genes IGK and IGL, thereby contributing to the maturation of the B-cell receptor, 20 whereas the present study shows that these light chain genes are infrequently rearranged in TCF3-rearranged BCP-ALL. Inhibition of TCF3 is essential for the successful production of high-affinity immunoglobulins, a process that is mediated via a negative-feedback loop of the mature B-cell receptor. 21 Given the presently available data, we would like to postulate that the differentiation of TCF3-rearranged BCP-ALL is arrested at an early stage in B-cell development, most likely resembling the compartment of pre-B-II-large cells in normal hematopoiesis before IRF4 triggers the rearrangements of immunoglobulin light chains. 20 The aberrantly high levels of IRF4 together with activated pre-BCR signaling may trigger an uncontrolled expansion of TCF3-rearranged cells in vivo at the expense of differentiation into more mature B cells. In correspondence, the relative sensitivity of TCF3-rearranged leukemic cells for Ibrutinib-without need for external stimuli other than those provided by the culture medium-and the aberrant expression profile of pre-BCR-related proteins suggests that the pre-BCR pathway is more activated in TCF3-rearranged compared with non-TCF3-rearranged leukemic cells.
The prognosis of children with TCF3-rearranged leukemia has improved during consecutive trials by optimizing the regimens with traditional chemotherapeutic drugs. 22 Implementation of more specific, that is, targeted, drugs may further improve prognosis and/or reduce the side effects of current chemotherapeutics by allowing a dosage reduction. Early clinical trials show that objective response rates can be obtained with Ibrutinib in 60-75% of patients with relapsed or refractory B-cell malignancies. 11, 23 A phase II study in adult patients with chronic lymphoid leukemia indicates that monotherapy with Ibrutinib might be effective even in high-risk cases with limited adverse effects. 23 These early clinical trial observations together with the findings presented in this preclinical study provide a strong rationale to design studies with agents interfering with pre-BCR signaling (for example, Ibrutinib) in children with TCF3-rearranged BCP-ALL.
